Market capitalization | $1.60b |
Enterprise Value | $1.35b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.16 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-269.80m |
Free Cash Flow (TTM) Free Cash Flow | $-210.55m |
Cash position | $278.83m |
As a Free StocksGuide user, you can view scores for all 6,900 stocks worldwide.
15 Analysts have issued a Rocket Pharmaceuticals, Inc. forecast:
15 Analysts have issued a Rocket Pharmaceuticals, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -8.72 -8.72 |
28%
28%
|
|
EBITDA | -261 -261 |
4%
4%
|
EBIT (Operating Income) EBIT | -270 -270 |
4%
4%
|
Net Profit | -253 -253 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
Head office | United States |
CEO | Gaurav Shah |
Employees | 268 |
Founded | 1999 |
Website | www.rocketpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.